Drug Profile
Research programme: regeneration therapies - Kolon TissueGene
Alternative Names: TG-B; TG-D; TG-NLatest Information Update: 21 Mar 2018
Price :
$50
*
At a glance
- Originator TissueGene
- Developer Kolon TissueGene
- Class Cell therapies; Proteins
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fracture; Intervertebral disc degeneration; Osteoarthritis; Osteoporosis; Peripheral nervous system diseases; Spinal cord injuries
Most Recent Events
- 16 Mar 2018 TissueGene is now called Kolon TissueGene
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fracture in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Intervertebral-disc-degeneration in USA (Parenteral)